Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nano Labs (NA) Cash & Equivalents (2021 - 2025)

Nano Labs' Cash & Equivalents history spans 5 years, with the latest figure at $1.2 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $1.2 million for Q4 2025, down 73.45% from a year ago — trailing twelve months through Dec 2025 was $1.2 million (down 73.45% YoY), and the annual figure for FY2025 was $1.2 million, down 73.19%.
  • Cash & Equivalents for Q4 2025 was $1.2 million at Nano Labs, down from $4.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $12.3 million in Q4 2022 to a low of $13853.4 in Q4 2021.
  • The 5-year median for Cash & Equivalents is $4.5 million (2024), against an average of $5.0 million.
  • The sharpest move saw Cash & Equivalents soared 89023.71% in 2022, then tumbled 73.45% in 2025.
  • Year by year, Cash & Equivalents stood at $13853.4 in 2021, then soared by 89023.71% to $12.3 million in 2022, then crashed by 45.82% to $6.7 million in 2023, then plummeted by 32.51% to $4.5 million in 2024, then tumbled by 73.45% to $1.2 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $1.2 million, $4.5 million, and $6.7 million for Q4 2025, Q4 2024, and Q4 2023 respectively.